Aspira Women's Health Files 8-K on Agreements and Equity Sales

Ticker: AWHL · Form: 8-K · Filed: 2025-09-25T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, equity-sale, financial-statements

TL;DR

Aspira Women's Health (AWH) filed an 8-K detailing new deals and stock sales.

AI Summary

Aspira Women's Health Inc. filed an 8-K on September 25, 2025, reporting on events that occurred on September 19, 2025. The filing indicates an entry into a material definitive agreement, unregistered sales of equity securities, and includes financial statements and exhibits. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware.

Why It Matters

This 8-K filing signals significant corporate actions, including new agreements and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities and material definitive agreements, which can introduce financial and operational risks.

Key Players & Entities

Aspira Women's Health Inc. (company) — Registrant
September 19, 2025 (date) — Earliest event reported
September 25, 2025 (date) — Date of report
Vermillion, Inc. (company) — Former company name
Ciphergen Biosystems Inc (company) — Former company name
Abiotic Systems (company) — Former company name

FAQ

What type of material definitive agreement did Aspira Women's Health Inc. enter into?

The filing indicates an entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.

What was the date of the earliest event reported in this 8-K filing?

The earliest event reported was on September 19, 2025.

When was this 8-K form filed with the SEC?

This 8-K form was filed on September 25, 2025.

What are some of the former names of Aspira Women's Health Inc. mentioned in the filing?

The filing mentions former names including Vermillion, Inc., Ciphergen Biosystems Inc, and Abiotic Systems.

What are the main items reported in this 8-K filing?

The main items reported are entry into a material definitive agreement, unregistered sales of equity securities, and financial statements and exhibits.

From the Filing

0001493152-25-014925.txt : 20250925 0001493152-25-014925.hdr.sgml : 20250925 20250925160142 ACCESSION NUMBER: 0001493152-25-014925 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250919 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250925 DATE AS OF CHANGE: 20250925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 251343692 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm 8-K false 0000926617 0000926617 2025-09-19 2025-09-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): September 19, 2025   ASPIRA WOMEN’S HEALTH INC. (Exact name of registrant as specified in its charter)   Delaware   001-34810   33-0595156 (State or other jurisdiction of   (Commission   (IRS Employer incorporation or organization)   File Number)   Identification No.)   12117 Bee Caves Road , Building III , Suite 100 Austin , TX 78738 (Address of principal executive office) (Zip Code)   (512) 519-0400 (Registrants’ telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   AWHL   OTC QB Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)   Emerging Growth Company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01 Entry into a Material Definitive Agreement.   As previously reported, on March 5, 2025, Aspira Women’s Health Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) wi